Arvinas Inc
$ 12.37
0.57%
24 Feb - close price
- Market Cap 908,176,000 USD
- Current Price $ 12.37
- High / Low $ 12.44 / 11.00
- Stock P/E N/A
- Book Value 7.97
- EPS -0.81
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.10 %
- 52 Week High 18.93
- 52 Week Low 5.90
About
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$13.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-06 | 2025-05-01 | 2025-02-11 | 2024-10-30 | 2024-07-30 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-08 | 2023-05-05 | 2023-02-23 |
| Reported EPS | -0.48 | -0.84 | 1.14 | -0.63 | -0.68 | -0.49 | -0.97 | -2.53 | -1.18 | -1.25 | -1.54 | -1.56 |
| Estimated EPS | -0.76 | -0.89 | -0.97 | -0.96 | -0.87 | -0.86 | -1.42 | -1.27 | -1.58 | -1.65 | -1.51 | -1.22 |
| Surprise | 0.28 | 0.05 | 2.11 | 0.33 | 0.19 | 0.37 | 0.45 | -1.26 | 0.4 | 0.4 | -0.03 | -0.34 |
| Surprise Percentage | 36.8421% | 5.618% | 217.5258% | 34.375% | 21.8391% | 43.0233% | 31.6901% | -99.2126% | 25.3165% | 24.2424% | -1.9868% | -27.8689% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.4955 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARVN
2026-02-25 06:52:58
Arvinas, a New Haven-based biotech firm, has appointed Randy Teel GRD ’08 as its new CEO, signaling a shift in focus towards developing multiple early-stage drugs in oncology and neurology. This change comes after the company ended its partnership with Pfizer for its flagship oncology drug. The timing aligns with an increase in activity and investment in the biotech sector, though Teel emphasizes a continued focus on producing robust data from their early-phase drugs.
2026-02-24 23:52:58
Wedbush maintained a Neutral rating for Arvinas, Inc. (ARVN) and raised its price target from $9 to $11 on February 24, 2026. This action signals an improved valuation without a change in the firm's overall conviction, leading to a 3.04% intraday rise in Arvinas shares. Investors are advised to view the price target increase as a valuation adjustment rather than a definitive buy signal, with Meyka AI rating ARVN a B grade.
2026-02-24 22:52:57
Arvinas, Inc., a biopharmaceutical company, has released its annual 10-K report detailing its financial performance, business operations, and strategic initiatives. The report highlights the company's focus on developing PROTAC protein degraders, progress in clinical trials for oncology and neurology, and ongoing collaborations with major pharmaceutical companies. Despite significant financial risks due to sustained losses and reliance on external funding, Arvinas plans to advance several product candidates and continue pursuing strategic partnerships and capital management.
2026-02-24 19:52:58
Wedbush has increased its price target for Arvinas Inc. (NASDAQ:ARVN) to $11 from $9, maintaining a Neutral rating, despite the stock already trading above this new target. The revision follows the company's fourth-quarter financial results for 2025 and ongoing pipeline progress for several key drug candidates. While Arvinas reported significant shortfalls in Q4 2025 earnings and revenue, Wedbush's updated outlook reflects continued advancements in various clinical programs expected throughout 2026.
2026-02-24 15:52:58
Arvinas (NASDAQ:ARVN) experienced a significant gap down in its stock price after announcing weaker-than-expected quarterly earnings, missing analyst consensus estimates for both EPS and revenue. The company reported a loss of ($1.10) per share against an estimated ($0.55), and revenue of $9.5 million, an 84% year-over-year decline. Despite some analyst upgrades and "Buy" ratings, company insiders have recently sold shares, while institutional ownership remains high at 95.19%.
2026-02-24 10:52:58
Arvinas reported its Q4 and full-year 2025 financial results, alongside a corporate update, revealing $685.4 million in cash, cash equivalents, and marketable securities, providing a cash runway into the second half of 2028. The company highlighted significant pipeline progress with multiple clinical readouts expected in 2026, including data for ARV-102, ARV-806, and ARV-393, and the advancement of vepdegestrant towards a June 5, 2026, FDA PDUFA date for breast cancer treatment. Cost reduction efforts were evident in decreased R&D and G&A expenses, though the company experienced a market reaction of +0.57% to the news despite historically seeing negative price movements post-earnings.
